HYPD · Hyperion Defi, Inc.
$2.57
+0.23 (+9.83%)
At close · Jul 30
Market Cap
$35.47M
Shares
15.16M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.34
Open$2.39
Day$2.34–2.47
52W$2.34–15.00
Avg vol 30d507K
Short int1.5M · 10.1% float · 5.2d
Short vol72%
Last earningsAug 12, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 15
Up next
Next earnings call
Aug 12, 2026
Scheduled
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−40%
below
Price vs 50-day avg
−25%
below
RSI (14)
32
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−25%
trailing
6-month return
−36%
trailing
YTD return
−34%
this year
Relative strength
−42%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
4 of 29 funds reported for Jun 30 · net -800 sh shares
Insider flow
Accumulating
Net +$29.6K over 90 days · 0% sells
Short interest
Rising
10.11% of float · ▲ +13.4% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
29 holders — mid 1-yr range
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+1319%
Y/Y
Gross margin
63%
expanding
EPS growth
+84%
Y/Y
Free cash flow
$-14.9M
Balance sheet
$6.4M
net cash
Quant / Vol
risk profile
Volatility
132%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
9.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 14, 2026
Adjusted Gross Profit
· FY'26
Non-GAAP
Maintained
$5M – $7M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−40%
Bearish
Price vs 50-day avg
−25%
Bearish
RSI (14)
32
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
4 of 29 funds reported for Jun 30 · net -800 sh shares
Insider flow
Accumulating
Net +$29.6K over 90 days · 0% sells
Short interest
Rising
10.11% of float · ▲ +13.4% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
29 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $2
Now $2 · 0%
52-wk high $15
vs 200-day avg -40%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $19,488,132 | Q1 2026 | — |
| Adjusted Gross Profit non-GAAP | $960K | Q1 2026 | — |
| Cash, Cash Equivalents, and USDH | $9.1M | Q1 2026 | — |
| Gross HYPE Tokens | 1.88M | Q1 2026 | — |
| Multiple vs. Staking Yield non-GAAP | 3.1 | Q1 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HYPD
this stock
Hyperion Defi, Inc.
|
$35.47M | -34.3% | +1414.0% | — | 10.1% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.67B | +6.6% | +46.2% | 28.7 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.91B | -9.8% | +20.8% | 17.5 | 3.4% |
|
ARGX
Argenx SE
|
$55.21B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HYPD | -15.2% | -25.5% | -35.9% | -25.5% | -34.3% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -12.8% | -23.2% | -42.2% | -23.2% | -41.2% |